RxDoctor Payments Data

Olayinka Akinwumiju, MD

Psychiatry · Olive Branch, MSNPI 1831115419

Payments from drug & device makers

$1,386in general payments, 2019–2025

Across 69 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$700
  • Sunovion Pharmaceuticals Inc.$163
  • Teva Pharmaceuticals USA, Inc.$152
  • Indivior Inc.$149
  • Alkermes, Inc.$66
  • Neuronetics, Inc.$52
  • plus $104 from 4 others

What the payments were for

  • Food & beverage$1,386100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,386 in reported general payments places this provider in the 65th percentile of 219 psychiatry providers in Mississippi.

See all psychiatry providers in Mississippi

Medicare billing

Part B allowed, 2024
$177,665
Medicare patients
228
Services billed
2,598

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate33$250,610
Invega SustennaPaliperidone Palmitate31$90,615
PerserisRisperidone31$88,188
VraylarCariprazine Hcl33$47,378
FanaptIloperidone11$22,659
Aripiprazole191$15,643
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl98$13,494
Fluphenazine Hcl75$11,315
SuboxoneBuprenorphine Hcl/Naloxone Hcl23$7,553
Oxcarbazepine149$7,484
BelsomraSuvorexant17$7,300
Haloperidol145$6,598
Chlorpromazine Hcl14$6,498
Ziprasidone Hcl79$5,879
Paliperidone ErPaliperidone25$5,617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$36$250,61033 claims
Indivior Inc.Perseris, Suboxone$149$95,74154 claims
AbbVieVraylar$700$47,37833 claims
Vanda Pharmaceuticals Inc.Fanapt$15$22,65911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 219 psychiatry providers in Mississippi.

Other psychiatry in Olive Branch

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →